Today: 30 June 2026
Browse Category

NASDAQ:ZEAL 6 March 2026 - 8 June 2026

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma Shares Sink 25% After Trial Results

Zealand Pharma shares tumbled in Copenhagen on Monday. The drop followed investor worries over side effects tied to Boehringer Ingelheim’s survodutide, which offset hope around the drug's fat-loss results. Zealand’s investor page listed the shares at 241.40 Danish crowns, off 26.02%. Reuters said the stock led declines on Europe’s STOXX 600 early in the session. The timing was key. Copenhagen’s stock market was open, trading on Nasdaq ran its usual 09:00 to 17:00 hours. The exchange calendar had June 5, Denmark’s Constitution Day, listed as a holiday, but not June 8. Monday was the first regular session for the market to react to the Sunday updates out of the American Diabetes Association meeting.
8 June 2026
·
Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race

Zealand Pharma A/S shares plunge as petrelintide results trail Lilly in obesity race

Zealand Pharma shares plunged Friday, dropping 32.53% to 249.10 Danish crowns by 10:40 a.m. local time. Investors punished the Danish biotech after fresh data on its obesity drug petrelintide disappointed, sending the stock toward a record single-day loss and slashing around 8.3 billion crowns from its market cap. This shift is significant: petrelintide is central to Zealand’s ambitions in obesity—and to Roche’s bid for a leading spot in the weight-loss drug race. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound currently dominate; both are GLP-1 drugs that suppress appetite via gut hormone action. Roche last year struck a deal valued at up to $5.3 billion for the rights to Zealand’s compound.
6 March 2026
·

Stock Market Today

  • Maruti Suzuki up 4% after Jefferies upgrade, higher target price
    June 30, 2026, 3:34 AM EDT. Maruti Suzuki India shares rallied almost 4% on June 30 after Jefferies boosted its rating to "Buy" and lifted the price target to Rs 16,500, a call that points to 23% upside. Jefferies said the upgrade was driven by stronger passenger vehicle demand and softer input costs from lower crude and metals. The automaker, which leads the Indian market with a valuation near Rs 4.4 lakh crore, is up 12.6% over the past year against a weak Nifty 50. The brokerage firm also raised EPS estimates for FY27-FY29 and sees 16% CAGR in earnings through FY29. Broader indices Sensex and Nifty slipped, held back by IT, FMCG, metals, and banking stocks, even as Maruti outperformed.
Go toTop